# Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A

> **NCT04644575** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bioverativ, a Sanofi company** · enrollment: 261 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** efanesoctocog alfa (BIVV001)

## Key facts

- **NCT ID:** NCT04644575
- **Lead sponsor:** Bioverativ, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-23
- **Primary completion:** 2027-01-15
- **Final completion:** 2027-01-15
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04644575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04644575, "Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04644575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*